Clinical data presented at the American Diabetes Association (ADA) conference in New Orleans support's Abbott’s claim that its FreeStyle Libre 3 system is the first and only 14-day continuous glucose monitoring (CGM) system to achieve a sub-8% overall mean absolute relative difference (MARD).
Clinical data from a 100-patient, 14-day non-randomized study, presented by Abbott at the ADA meeting, showed FreeStyle Libre 3...